|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
DeLellis R and Williams ED: Tumours of the
thyroid and parathyroid. World Health Organization Classification
of Tumours. Pathology and Genetics of Tumours of Endocrine Organs.
DeLellis R and Williams ED: 8. IARC Press; pp. 51–56. 2004
|
|
3
|
Romei C, Fugazzola L, Puxeddu E, Frasca F,
Viola D, Muzza M, Moretti S, Nicolosi ML, Giani C, Cirello V, et
al: Modifications in the papillary thyroid cancer gene profile over
the last 15 years. J Clin Endocrinol Metab. 97:E1758–E1765. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Romei C, Ciampi R and Elisei R: A
comprehensive overview of the role of the RET proto-oncogene in
thyroid carcinoma. Nat Rev Endocrinol. 12:192–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kouvaraki MA, Shapiro SE, Perrier ND, Cote
GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE and Evans DB: RET
proto-oncogene: A review and update of genotype-phenotype
correlations in hereditary medullary thyroid cancer and associated
endocrine tumors. Thyroid. 15:531–544. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nikiforov YE, Rowland JM, Bove KE,
Monforte-Munoz H and Fagin JA: Distinct pattern of ret oncogene
rearrangements in morphological variants of radiation-induced and
sporadic thyroid papillary carcinomas in children. Cancer Res.
57:1690–1694. 1997.PubMed/NCBI
|
|
7
|
Agrawal N, A R, Aksoy BA, Ally A, Arachchi
H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB and Behera
M: Integrated genomic characterization of papillary thyroid
carcinoma. Cell. 159:676–690. 2014. View Article : Google Scholar :
|
|
8
|
Network CGAR; Cancer Genome Atlas Research
Network: Integrated genomic characterization of papillary thyroid
carcinoma. Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo D, Holmlund C, Henriksson R and Hedman
H: The LRIG gene family has three vertebrate paralogs widely
expressed in human and mouse tissues and a homolog in Ascidiacea.
Genomics. 84:157–165. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holmlund C, Nilsson J, Guo D, Starefeldt
A, Golovleva I, Henriksson R and Hedman H: Characterization and
tissue-specific expression of human LRIG2. Gene. 332:35–43. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nilsson J, Vallbo C, Guo D, Golovleva I,
Hallberg B, Henriksson R and Hedman H: Cloning, characterization,
and expression of human LIG1. Biochem Biophys Res Commun.
284:1155–1161. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Poulin EJ and Coffey RJ: LRIG1 is
a triple threat: ERBB negative regulator, intestinal stem cell
marker and tumour suppressor. Br J Cancer. 108:1765–1770. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lindquist D, Kvarnbrink S, Henriksson R
and Hedman H: LRIG and cancer prognosis. Acta Oncol. 53:1135–1142.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krig SR, Frietze S, Simion C, Miller JK,
Fry WH, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW, et al:
Lrig1 is an estrogen-regulated growth suppressor and correlates
with longer relapse-free survival in ERα-positive breast cancer.
Mol Cancer Res. 9:1406–1417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Willis S, Villalobos VM, Gevaert O,
Abramovitz M, Williams C, Sikic BI and Leyland-Jones B: Single Gene
Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis. PLoS One.
11:e01491832016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lindström AK, Ekman K, Stendahl U, Tot T,
Henriksson R, Hedman H and Hellberg D: LRIG1 and squamous
epithelial uterine cervical cancer: Correlation to prognosis, other
tumor markers, sex steroid hormones, and smoking. Int J Gynecol
Cancer. 18:312–317. 2008. View Article : Google Scholar
|
|
17
|
Tanemura A, Nagasawa T, Inui S and Itami
S: LRIG-1 provides a novel prognostic predictor in squamous cell
carcinoma of the skin: Immunohistochemical analysis for 38 cases.
Dermatol Surg. 31:423–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lindquist D, Näsman A, Tarján M,
Henriksson R, Tot T, Dalianis T and Hedman H: Expression of LRIG1
is associated with good prognosis and human papillomavirus status
in oropha-ryngeal cancer. Br J Cancer. 110:1793–1800. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sheu JJ, Lee CC, Hua CH, Li CI, Lai MT,
Lee SC, Cheng J, Chen CM, Chan C, Chao SC, et al: LRIG1 modulates
aggressiveness of head and neck cancers by regulating
EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling.
Oncogene. 33:1375–1384. 2014. View Article : Google Scholar
|
|
20
|
Kvarnbrink S, Karlsson T, Edlund K,
Botling J, Lindquist D, Jirström K, Micke P, Henriksson R,
Johansson M and Hedman H: LRIG1 is a prognostic biomarker in
non-small cell lung cancer. Acta Oncol. 54:1113–1119. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang B, Dai C, Tan R, Zhang B, Meng X, Ye
J, Wang X, Wei L, He F and Chen Z: Lrig1 is a positive prognostic
marker in hepatocellular carcinoma. Onco Targets Ther. 9:7071–7079.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gur G, Rubin C, Katz M, Amit I, Citri A,
Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, et al:
LRIG1 restricts growth factor signaling by enhancing receptor
ubiquitylation and degradation. EMBO J. 23:3270–3281. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Laederich MB, Funes-Duran M, Yen L,
Ingalla E, Wu X, Carraway KL III and Sweeney C: The leucine-rich
repeat protein LRIG1 is a negative regulator of ErbB family
receptor tyrosine kinases. J Biol Chem. 279:47050–47056. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miller JK, Shattuck DL, Ingalla EQ, Yen L,
Borowsky AD, Young LJ, Cardiff RD, Carraway KL III and Sweeney C:
Suppression of the negative regulator LRIG1 contributes to ErbB2
overexpression in breast cancer. Cancer Res. 68:8286–8294. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stutz MA, Shattuck DL, Laederich MB,
Carraway KL III and Sweeney C: LRIG1 negatively regulates the
oncogenic EGF receptor mutant EGFRvIII. Oncogene. 27:5741–5752.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shattuck DL, Miller JK, Laederich M, Funes
M, Petersen H, Carraway KL III and Sweeney C: LRIG1 is a novel
negative regulator of the Met receptor and opposes Met and Her2
synergy. Mol Cell Biol. 27:1934–1946. 2007. View Article : Google Scholar :
|
|
27
|
Ledda F, Bieraugel O, Fard SS, Vilar M and
Paratcha G: Lrig1 is an endogenous inhibitor of Ret receptor
tyrosine kinase activation, downstream signaling, and biological
responses to GDNF. J Neurosci. 28:39–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rondahl V, Holmlund C, Karlsson T, Wang B,
Faraz M, Henriksson R and Hedman H: Lrig2-deficient mice are
protected against PDGFB-induced glioma. PLoS One. 8:e736352013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alsina FC, Hita FJ, Fontanet PA, Irala D,
Hedman H, Ledda F and Paratcha G: Lrig1 is a cell-intrinsic
modulator of hippocampal dendrite complexity and BDNF signaling.
EMBO Rep. 17:601–616. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nilsson J, Starefeldt A, Henriksson R and
Hedman H: LRIG1 protein in human cells and tissues. Cell Tissue
Res. 312:65–71. 2003.PubMed/NCBI
|
|
31
|
Rossel M, Pasini A, Chappuis S, Geneste O,
Fournier L, Schuffenecker I, Takahashi M, van Grunsven LA, Urdiales
JL, Rudkin BB, et al: Distinct biological properties of two RET
isoforms activated by MEN 2A and MEN 2B mutations. Oncogene.
14:265–275. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Santoro M, Carlomagno F, Romano A, Bottaro
DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH,
et al: Activation of RET as a dominant transforming gene by
germline mutations of MEN2A and MEN2B. Science. 267:381–383. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang N, Kjellin H, Sofiadis A, Fotouhi O,
Juhlin CC, Bäckdahl M, Zedenius J, Xu D, Lehtiö J and Larsson C:
Genetic and epigenetic background and protein expression profiles
in relation to telomerase activation in medullary thyroid
carcinoma. Oncotarget. 7:21332–21346. 2016.PubMed/NCBI
|
|
34
|
Suzuki Y, Miura H, Tanemura A, Kobayashi
K, Kondoh G, Sano S, Ozawa K, Inui S, Nakata A, Takagi T, et al:
Targeted disruption of LIG-1 gene results in psoriasiform epidermal
hyperplasia. FEBS Lett. 521:67–71. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Acton DS, Velthuyzen D, Lips CJ and
Höppener JW: Multiple endocrine neoplasia type 2B mutation in human
RET oncogene induces medullary thyroid carcinoma in transgenic
mice. Oncogene. 19:3121–3125. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
van Veelen W, van Gasteren CJ, Acton DS,
Franklin DS, Berger R, Lips CJ and Höppener JW: Synergistic effect
of oncogenic RET and loss of p18 on medullary thyroid carcinoma
development. Cancer Res. 68:1329–1337. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo D, Nilsson J, Haapasalo H, Raheem O,
Bergenheim T, Hedman H and Henriksson R: Perinuclear leucine-rich
repeats and immunoglobulin-like domain proteins (LRIG1-3) as
prognostic indicators in astrocytic tumors. Acta Neuropathol.
111:238–246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hedman H, Lindström AK, Tot T, Stendahl U,
Henriksson R and Hellberg D: LRIG2 in contrast to LRIG1 predicts
poor survival in early-stage squamous cell carcinoma of the uterine
cervix. Acta Oncol. 49:812–815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Holmlund C, Haapasalo H, Yi W, Raheem O,
Brännström T, Bragge H, Henriksson R and Hedman H: Cytoplasmic
LRIG2 expression is associated with poor oligodendroglioma patient
survival. Neuropathology. 29:242–247. 2009. View Article : Google Scholar
|
|
41
|
Muller S, Lindquist D, Kanter L,
Flores-Staino C, Henriksson R, Hedman H and Andersson S: Expression
of LRIG1 and LRIG3 correlates with human papillomavirus status and
patient survival in cervical adenocarcinoma. Int J Oncol.
42:247–252. 2013. View Article : Google Scholar
|
|
42
|
Neirinckx V, Hedman H and Niclou SP:
Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases
for cancer therapy. Biochim Biophys Acta. 1868:109–116.
2017.PubMed/NCBI
|
